##plugins.themes.academic_pro.article.sidebar##

Published
Feb 25, 2025
Download
PDF
Statistic
Read Counter : 17 Download : 5

Main Article Content

Abstract

Background: Progression-free survival (PFS) is a parameter to measures the progression of wild type adenocarcinoma lung cancer. Literature studies have shown that the combination platinum based-pemetrexed chemotherapy is more effective to prolonged progressivity of wild type adenocarcinoma.


Aim: The aim of study to compared the PSF of wild type adenocarcinoma patients receiving cisplatin-pemetrexed and pemetrexed-carboplatin regimens at Dr. Saiful Anwar Hospital in 2018-2021.


Methods: A retrospective cohort study based on medical record of wild type adenocarcinoma patients.


Results: The results showed that the administration of a carboplatin-pemetrexed regimen has prolonged PFS (median 4 months, 95% CI 2.657-5.343) compared to the cisplatin-pemetrexed regimen (median 2 months, 95% CI 0.988-3.012). In addition, the risk of lung cancer progression based on PFS is not significantly influenced by the Karnofsky scale value of 70-80 (72.2%, HR 0.278). On the other hand, a history of smoking increases the risk of lung cancer progression, although it does not have a significant effect (HR 1,538).


Conclusion: Administration of the carboplatin-pemetrexed regimen prolongs PFS up to a range of 10-16 months, although there is no statistically significant difference compared to the cisplatin-pemetrexed.

Article Details

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite
Agus Setyawan, U., Purnamawati, C., & Pratiwi, S. (2025). Progression Free Survival in Lung Cancer Adenocarcinoma Wild Type Patients with Pemetrexed Regimen Combination of Cisplatin compared to Carboplatin. Jurnal Klinik Dan Riset Kesehatan, 4(2), 87-94. https://doi.org/10.11594/jk-risk.04.2.2

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209–49.
2. Chan BA, Hughes BGM. Targeted therapy for non-small cell lung cancer: Current standards and the promise of the future. Translational Lung Cancer Research. 2015;4(1):36–54.
3. Jazieh AR, Al Sudairy R, Abu-Shraie N, Al Suwairi W, Ferwana M, Murad Mh. Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review. Annals of Tho-racic Medicine. 2013;8(4):204.
4. Minnelli C, Laudadio E, Mobbili G, Galeazzi R. Con-formational insight on WT-and mutated-EGFR re-ceptor activation and inhibition by epigallocate-chin-3-gallate: Over a rational basis for the design of selective non-small-cell lung anticancer agents. International Journal of Molecular Sciences. 2020;21(5):1–17.
5. Karampeazis A, Voutsina A, Souglakos J, Ken-tepozidis N, Giassas S, Christofillakis C, et al. Pemetrexed versus erlotinib in pretreated pa-tients with advanced non-small cell lung cancer: A Hellenic Oncology Research Group (HORG) ran-domized phase 3 study. Cancer. 2013 Aug 1;119(15):2754–64.
6. Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, et al. Efficacy and safety of erlotinib versus chemotherapy in sec-ond-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. The Lancet Oncology. 2012 Mar;13(3):300–8.
7. Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, et al. Erlotinib versus docet-axel as second-line treatment of patients with ad-vanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): A randomised con-trolled trial. The Lancet Oncology. 2013;14(10):981–8.
8. Zhou Q, Cheng Y, Yang JJ, Zhao MF, Zhang L, Zhang XC, et al. Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): A multicenter randomized trial. Annals of Oncology. 2014;25(12):2385–91.
9. Anwar J. Seri Buku Ajar Onkologi Toraks. Pen-gobatan Kanker Paru. I. Jakarta: PDPI; 2019. 7–24 p.
10. Xu T, Wu H, Jin S, Min H, Zhang Z, Shu Y, et al. Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report. Medicine (United States). 2017;96(33):0–4.
11. Cheng YJ, Wu R, Cheng ML, Du J, Hu XW, Yu L, et al. Carboplatin-induced hematotoxicity among patients with nonsmall cell lung cancer: Analysis on clinical adverse events and drug-gene interac-tions. Oncotarget. 2017;8(19):32228–36.
12. Heist RS. First-Line Systemic Therapy for Non–Small Cell Lung Cancer. Hematology/Oncology Clinics of North America. 2017;31(1):59–70.
13. USAMI E, KIMURA M, IWAI M, TAKENAKA S, TERAMACHI H, YOSHIMURA T. Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting. Mo-lecular and Clinical Oncology. 2016 Apr;4(4):591–6.
14. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for di-agnosis, treatment and follow-up. Annals of On-cology. 2018 Oct;29:iv192–237.
15. Sutandyo, N. Suratman E. Non-Small Cell Lung Carcinoma in Women: A Retrospective Cohort Study in Indonesia. Acta medica Indonesiana. 2018;50:4.
16. Nicholsxon AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. Journal of Thoracic Oncology. 2022;17(3):362–87.
17. Park SE, Noh JM, Kim YJ, Lee HS, Cho JH, Lim SW, et al. EGFR mutation is associated with short pro-gression-free survival in patients with stage III non-squamous cell lung cancer treated with con-current chemoradiotherapy. Cancer Research and Treatment. 2019;51(2):493–501.
18. Setyawan UA, Pratiwi SD, Fitryanto A, Suwandi GS, Sari FI, Novelia Z. Profile Of Lung Cancer From East Java Tertiary Hospital: Clinicopathological Profile. Chest. 2019;155(4):202A.
19. Kementrian Kesehatan Republik Indonesia, Komite Penanggulangan Kanker Nasional, Na-sional K. Panduan Penatalaksanaan Kanker Paru. Jakarta; 2017.
20. Kimura T et al. Phase II study of carboplatin and pemetrexed in advanced EGFR-wild-type non-squamous non-small cell lung cancer: The central Japan lung study group trial 0906. Anticancer Research. 2016;36(4):1767–71.
21. Pangribowo S. Beban Kanker di Indonesia. Pusat Data Dan Informasi Kesehatan Kementerian Kesehatan RI. 2019;1–16.
22. Tseng CH, Chiang CJ, Tseng J Sen, Yang TY, Hsu KH, Chen KC, et al. EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. Onco-target. 2017;8(58):98384–93.
23. Tseng CH, Chiang CJ, Tseng JS, Yang TY, Hsu KH, Chen KC, et al. EGFR mutation, smoking, and gen-der in advanced lung adenocarcinoma. Oncotar-get. 2017 Nov 17;8(58):98384–93.